ArticleThe journal of spinal cord medicine2019
Treatment of spasticity in spinal cord injury with botulinum toxin.
Article in The journal of spinal cord medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study.Journal of pediatric rehabilitation medicineTrial
- The use of botulinum toxin for spasticity in people with spinal cord injury: a scoping review.European journal of physical and rehabilitation medicine · 2026Article
- Article
- Neurogenic bladder pathophysiology, assessment and management after lumbar diseases.EFORT open reviews · 2025Review
- Effects of Botulinum Toxin-A for Spasticity and Nociceptive Pain in Individuals with Spinal Cord Injury: A Systematic Review and Meta-Analysis.Annals of rehabilitation medicine · 2024Article
- The Role of Botulinum Toxin Type-A in Spasticity: Research Trends from a Bibliometric Analysis.Toxins · 2024Review
- Management of spasticity in individuals with spinal cord injury in the era of COVID-19 pandemic societal restrictions.Spinal cord series and cases · 2023Article
- Association between brain N-acetylaspartate levels and sensory and motor dysfunction in patients who have spinal cord injury with spasticity: an observational case-control study.Neural regeneration research · 2023Article
- Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: An observational longitudinal study.Frontiers in neurology · 2023Article
- Article
- Is it Feasible to Use a Low-Cost Wearable Sensor for Heart Rate Monitoring within an Upper Limb Training in Spinal Cord Injured Patients?: A Pilot Study.Bioengineering (Basel, Switzerland) · 2022Article
- Concomitant Brain Injury and Spinal Cord Injury Management Strategies: A Narrative Review.Journal of personalized medicine · 2022Review
- Neurogenic Bladder Physiology, Pathogenesis, and Management after Spinal Cord Injury.Journal of personalized medicine · 2022Article
- Spasticity Management after Spinal Cord Injury: The Here and Now.Journal of personalized medicine · 2022Article
- The Effects of the Exposure of Musculoskeletal Tissue to Extracorporeal Shock Waves.Biomedicines · 2022Review
- Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury.International journal of molecular sciences · 2021Review
- Botulinum Toxin and Neuronal Regeneration after Traumatic Injury of Central and Peripheral Nervous System.Toxins · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextSpasticity is one of the most frequent complications in spinal cord injury (SCI), and is routinely managed with oral pharmacologic therapy. Botulinum toxin (BT) is not accepted as a treatment for spasticity in SCI in Spain but may be used in certain cases of focal distribution.
objectiveTo report the results with BT for treatment of spasticity in SCI. DESIGN AND
settingDescriptive retrospective study conducted at a specialist SCI rehabilitation center in Spain, covering patients first treated from 2012 through 2014, and successfully followed up for a minimum of 1 year. Data were collected on the following variables: demographic and SCI characteristics (level and grade); nature of spasticity, e.g. tone, distribution, spasms, articular involvement and pain; function; application of BT; tolerance and adverse reactions.
resultsThe study covered 90 patients, predominantly male with incomplete injuries. Improvement in tone as measured by the modified Ashworth scale was a mean of 1.17 points. Goniometric improvement was achieved in 65.6% and improvement in pain in 38.9% of cases. There were no adverse side-effects. Patients with focal spasticity showed a significantly greater improvement in tone (P < 0.0001). The earlier the BT injection, the greater the improvement in goniometric performance (P < 0.006) and pain (P < 0.033), with the best results being obtained within the first 6 months of clinical course. ASIA D injuries showed a greater improvement in tone (P < 0.0001).
conclusionsBT can be both an effective treatment for focal spasticity in SCI and a good coadjuvant for oral treatments in generalized spasticity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.